Obesity Trials in Las Vegas, United States
Conditions / Obesity / Las Vegas, United States
Obesity is a medical condition with active clinical research programs worldwide.
60 total trials for this combination
Showing top 10 of 60 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05556512 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | RECRUITING | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | ACTIVE_NOT_RECRUITING | — |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | RECRUITING | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT03574597 | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | COMPLETED | PHASE3 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |